As China emerges out of COVID-19, Diaceutics has investigated the impact of the pandemic on cancer testing and what the data reveals about challenges ahead for pharma and labs. Using this framework, we extended the analysis of cancer testing rates to the US to evaluate the short and long term impacts of the cancer test and treatment landscape with support from our partners Kantar Health. Insights and recommendations are sourced from the world’s largest repository of diagnostic testing data by Diaceutics.
Webinar: The Road to Recovery - How COVID-19 has impacted the global oncology diagnostic testing environment
11 September, 2020